Literature DB >> 11375256

Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits.

K Noguchi1, S Yamashiro, T Matsuzaki, M Sakanashi, J Nakasone, K Miyagi, M Sakanashi.   

Abstract

Chronic administration of erythropoietin (EPO) is often associated with hypertension in animals and humans. The aim of this study was to estimate whether 1-week treatment with EPO can affect the vascular endothelial function. Rabbits were given with EPO (400 iu kg(-1) s.c.) or saline each other day for 1 week. Hypotensive responses to intravenously given acetylcholine (ACh), endothelium-independent nitric oxide donors (NOC7, nitroprusside and nitroglycerin) and prostaglandin I2 were tested before and after administration of N(G)-nitro-L-arginine methyl ester (L-NAME), a specific nitric oxide synthase inhibitor, under pentobarbitone anaesthesia. Blood haemoglobin concentration in EPO group was significantly higher than that in control group, whereas baseline values of aortic pressure, heart rate and femoral vascular resistance were similar. The dose of ACh (172 ng kg(-1)) requiring for a 15 mmHg hypotension from the baseline in EPO group was apparently higher than that (55 ng kg(-1)) in control group. On the contrary, hypotensive responses to NOC7, nitroprusside, nitroglycerin and prostaglandin I2 were comparable between two groups. The extent of ACh-induced hypotension did not correlate with haemoglobin concentration. L-NAME significantly inhibited the ACh-induced vasodilating response in control group but did not in EPO group. In another set of rabbits, the same treatment with EPO also decreased vasodilating responses to carbachol, bradykinin and substance P besides ACh as compared with control group. These results indicate that 1-week treatment with EPO selectively attenuates depressor responses to endothelium-dependent vasodilators in anaesthetized rabbits, most likely due to inhibition of endothelial nitric oxide synthase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375256      PMCID: PMC1572793          DOI: 10.1038/sj.bjp.0704083

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  Blood pressure, erythropoietin, and nitric oxide.

Authors:  J Martin; S Moncada
Journal:  Lancet       Date:  1988-03-19       Impact factor: 79.321

2.  Chronic exercise enhances endothelium-mediated dilation of epicardial coronary artery in conscious dogs.

Authors:  J Wang; M S Wolin; T H Hintze
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

3.  Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.

Authors:  M B Hussain; A J Hobbs; R J MacAllister
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Biotransformation of glyceryl trinitrate to glyceryl dinitrate by human hemoglobin.

Authors:  B M Bennett; K Nakatsu; J F Brien; G S Marks
Journal:  Can J Physiol Pharmacol       Date:  1984-06       Impact factor: 2.273

5.  Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression.

Authors:  W C Sessa; K Pritchard; N Seyedi; J Wang; T H Hintze
Journal:  Circ Res       Date:  1994-02       Impact factor: 17.367

6.  Erythropoietin receptor mRNA expression in human endothelial cells.

Authors:  A Anagnostou; Z Liu; M Steiner; K Chin; E S Lee; N Kessimian; C T Noguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Stretch revealed three components in the hyperpolarization of guinea-pig coronary artery in response to acetylcholine.

Authors:  H C Parkington; M Tare; M A Tonta; H A Coleman
Journal:  J Physiol       Date:  1993-06       Impact factor: 5.182

8.  Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells.

Authors:  M Neusser; M Tepel; W Zidek
Journal:  Cardiovasc Res       Date:  1993-07       Impact factor: 10.787

Review 9.  Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy.

Authors:  A E Raine
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321

10.  Modulation of endothelium-dependent responses by chronic alterations of blood flow.

Authors:  V M Miller; L L Aarhus; P M Vanhoutte
Journal:  Am J Physiol       Date:  1986-09
View more
  6 in total

1.  The effect of insufficiency of tetrahydrobiopterin on endothelial function and vasoactivity.

Authors:  Satoshi Yamashiro; Yukio Kuniyoshi; Katsuya Arakaki; Kazufumi Miyagi; Kageharu Koja
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-11

Review 2.  Cardiovascular effects of erythropoietin an update.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  Adv Pharmacol       Date:  2010

3.  The impact of erythropoietin on short-term changes in phosphorylation of brain protein kinases in a rat model of traumatic brain injury.

Authors:  Samuel Valable; Gilles Francony; Pierre Bouzat; Marie-Cécile Fevre; Nouara Mahious; Valentine Bouet; Régine Farion; Emmanuel Barbier; Hana Lahrech; Chantal Remy; Edwige Petit; Christoph Segebarth; Myriam Bernaudin; Jean-François Payen
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-07       Impact factor: 6.200

4.  Erythrocyte migration and gap formation in rabbit blood clots in vitro.

Authors:  T Ueki; F Yazama; T Horiuchi; M Yamada
Journal:  Vet Res Commun       Date:  2007-12-18       Impact factor: 2.459

5.  Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure.

Authors:  Hye Yun Jeong; Eun Jung Ko; Sang Hoon Kim; Mi Jung Lee; Hye Jeong Cho; Dong Ho Yang; So Young Lee
Journal:  Yonsei Med J       Date:  2017-07       Impact factor: 2.759

6.  Activation of the β-common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles.

Authors:  Cody R Kilar; YanPeng Diao; Larysa Sautina; Sivakumar Sekharan; Shahar Keinan; Bianca Carpino; Kirk P Conrad; Rajesh Mohandas; Mark S Segal
Journal:  Physiol Rep       Date:  2018-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.